jaumebosch
@jaumebosch9
Followers
3K
Following
3K
Media
20
Statuses
2K
Catalan (now Swiss) Hepatologist passionate for portal hypertension. Chairman of the Baveno Cooperation. Likes sailing, music, books and pirates
Bern University, Inselspital
Joined April 2020
Mechanisms and implications of recompensation in cirrhosis - JHEP Reports.✅ Curious about current thoughts on Recompensation of Cirrhosis?.➡️ Proud to share with you our recent publication in cooperation with Salvatore Piano and Thomas Reiberger.
jhep-reports.eu
Decompensated cirrhosis has long been considered the irreversible end stage of liver disease, characterised by further decompensating events until death or liver transplantation. However, the...
2
35
81
Stiffness-induced modulation of ERG transcription factor in chronic liver disease | npj Gut and Liver. ✅ Congratulations Sonia Selicean for this nice piece of work underscoring the role of ERG in mechanotransduction and inflammation in ACLD!
nature.com
npj Gut and Liver - Stiffness-induced modulation of ERG transcription factor in chronic liver disease
0
2
16
RT @paulin_mendoza: @docberza @MasoodiMojgan @jaumebosch9 @MattiasMandorf1 @GeorgSemmler 🆕 Our study of Cirrhosis regresión in @jhepatolog….
0
6
0
RT @docberza: Proud of this study on cirrhosis regression - many more questions remain to be answered! 👍🏻🌟 @paulin_mendoza @MasoodiMojgan @….
0
3
0
✅ More data suggesting Apixaban as safer than Rivaroxaban/Warfarin in cirrhosis!.✅ Annals of Internal Medicine: ➡️ @BavenoCoop .@ebtapper.
acpjournals.org
Background: Apixaban, rivaroxaban, and warfarin have shown benefit for preventing major ischemic events, albeit with increased bleeding risk, among patients in the general population with atrial...
0
32
88
✅ interested in factors modulating cirrhosis regression after control of the etiology?. ➡️ Brand new in JHep! Metabolic phenotyping of patients with Advanced Chronic Liver Disease for better characterization of Cirrhosis Regression.@yulymendozab
1
10
35
RT @docberza: Proud of our doctoral student Yeldos Nulan presenting orally his poster on how carvedilol modulates the vascular biology of c….
0
6
0
RT @docberza: Getting ready for a great EASL ILC - don’t forget to join the Baveno Cooperation Track Hub on Saturday! @ggarciatsao @Reiberg….
0
8
0
RT @JSGracia: The Liver Vascular Biology Lab of @idibaps @hospitalclinic @CIBERehd will be part of #LiverSinusoid24!. We are already in Chi….
0
3
0
RT @AleksanderKrag: It is with great sorrow to learn about the passing of Stephen Harrison, giant in the field, leader, inspirator, innovat….
0
7
0
RT @ebtapper: Stephen Harrison had a massive, positive, impact on the field. He produced landmarks in the epidemiology of NAFLD/MASLD, non-….
0
35
0
RT @JSGracia: Many thanks to all co-authors, including K Ikeda, @GSzaboMD, @MartiOR92, @PeterMcMac, P Lalor, F Braet, E Wisse, @prakramacha….
0
4
0
✅ Most interesting study! It shows the explanation for the early presinusoidal component in portal hypertension (PH) in cholestatic liver disease. ➡️ Please note that obliteration of portal venules also occurs in viral cirrhosis!.@BavenoCooperation
pathsocjournals.onlinelibrary.wiley.com
The effects of the obliteration of portal venules (OPV) in cirrhotic portal hypertension are poorly understood. To investigate its contribution to portal hypertension in biliary cirrhosis and its...
0
15
51
⚠️ What happens where papers are not (well) reviewed?. 1) erroneous findings leading to:.2) confusion, .3) discredit,.4) unnecessary refutation studies. Perfect exemple of what should NOT be published!.➡️ NO FAKE NEWS please!.#livertwitter.#Baveno Coop.
wjgnet.com
Hepatic venous pressure gradient: Inaccurately estimates portal venous pressure gradient in alcoholic cirrhosis and portal hypertension
1
3
25
RT @Dr_Ampuero: “El mayor enemigo del talento es un mediocre con poder que quiere ocultar su incompetencia”. Es de hace cinco años pero m….
0
11
0
RT @MarionaGraupera: Extremely happy to have the opportunity to approach key questions with an amazing team @RuiBenedito_ and @AlejoFratice….
0
5
0
⚠️ An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease | Nature Medicine. ➡️ Further rationale for using suppressors of thyroid hormone receptor beta regulon activity for MASLD.#livertwitter
nature.com
Nature Medicine - SteatoSITE is an open resource that integrates histopathologic assessments, transcriptomic data and longitudinal electronic health records for a cohort of 940 patients with...
1
10
29
Excellent Science and Efucuation at the 2023 BCLC UPDATE ON HCC
0
4
26